TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today gastroenterology roundup published November 5, 2026, highlights estimates that gallbladder and biliary diseases affected more than 264 million people and contributed to over 146,000 deaths worldwide in 2023. It also summarizes research on low-dose amitriptyline for IBS and a study linking rectal location of large polyps with greater odds of invasive cancer and recurrence after removal.
More than 264 million people had gallbladder or biliary diseases worldwide in 2023, and those conditions contributed to over 146,000 deaths, according to research highlighted in a November 5 MedPage Today gastroenterology roundup. The report also flags studies examining whether symptom profiles predict response to low-dose amitriptyline for IBS and whether large polyps in the rectum carry different risks from those in the colon.
The global estimates cover conditions including cholelithiasis, cholecystitis and cholangitis. The figures were reported from research published in The Lancet Gastroenterology & Hepatology. The roundup gives the total number of people affected and deaths attributed to the group of diseases, but does not provide further breakdowns by condition or region.
For irritable bowel syndrome, the cited study in Clinical Gastroenterology and Hepatology asks whether particular gastrointestinal and psychological symptom profiles can predict response to low-dose amitriptyline. The roundup does not report the study’s results, the size or makeup of its participant group, or whether any symptom profile reliably predicted benefit.
A retrospective cohort study from Poland, published in Gut, found that rectal location among patients who had endoscopic mucosal resection of large colorectal polyps was associated with a higher likelihood of invasive cancer and recurrence than colon location. The roundup does not give the size of the difference or details needed to determine how the findings should affect care for an individual patient.
Three Findings With Different Clinical Stakes
The mortality estimate signals a substantial global burden from gallbladder and biliary disease, while the IBS study addresses whether patient symptoms could help identify who responds to an existing medicine. Those questions matter to researchers and clinicians, but the roundup alone does not establish new treatment guidance or show that amitriptyline works better for a particular group.
The polyp findings may be relevant to how clinicians interpret risk after removal of large lesions, because the study reports different outcomes by location. However, an association in a retrospective cohort does not by itself prove that rectal location causes cancer or recurrence. The report provides no recommendation to change surveillance schedules or treatment.
Products Worth Considering
Hyperice Hypervolt Go 3 Portable Percussion Massage Gun with Carry Case
Therabody Theragun Mini 3rd Gen Massage Gun (Travel Essential, Black)
Fitbit Charge 6 Fitness Tracker – Obsidian/Black
As an affiliate, we earn on qualifying purchases.
Studies Behind the Roundup
The source is a short MedPage Today gastroenterology and hepatology roundup by Managing Editor Ian Ingram, published November 5, 2026. It summarizes findings and developments from several journals rather than presenting one new, unified study. The biliary disease estimate refers specifically to 2023; the other items concern separate research questions and patient groups.
The same roundup mentions other developments, including proposed consensus definitions for acute-on-chronic liver failure from global liver societies and a U.S. Health and Human Services inspector general report finding that fewer than one in four Medicaid beneficiaries with hepatitis C received treatment within six months of testing. These are separate items and do not change the scope of the three findings covered here.
Key Study Details Not Provided
The roundup does not include the underlying papers’ full methods, participant numbers, confidence intervals or detailed results. For the 2023 death estimate, it gives no regional or disease-specific breakdown. For the amitriptyline research, it does not state which profiles were assessed or whether they predicted response. For the polyp study, it does not report absolute risks, follow-up duration or the degree to which patient and lesion characteristics were accounted for.
It is also unclear whether the findings have prompted changes to clinical guidelines. The reported associations should not be read as individualized medical advice, and the roundup does not establish that any treatment or surveillance approach is appropriate for every patient.
Full Papers and Guidance Matter
The next step for readers seeking more detail is to consult the original journal studies cited in the roundup, particularly for methods and quantitative results absent from the summary. Further research would be needed to test whether symptom profiles can consistently predict amitriptyline response and to clarify how rectal versus colonic location affects outcomes after large-polyp resection.
Any change to practice would depend on fuller evidence and guidance from relevant professional bodies. The roundup reports no scheduled policy decision or announced change in treatment recommendations.
Key Questions
How many people had gallbladder or biliary disease in 2023?
The research cited by MedPage Today estimated that more than 264 million people worldwide had gallbladder or biliary diseases in 2023. The conditions together contributed to over 146,000 deaths.
What did the IBS study investigate?
The study asked whether gastrointestinal and psychological symptom profiles could predict response to low-dose amitriptyline. The roundup does not provide its results or identify a profile shown to predict benefit.
What did researchers report about large rectal polyps?
A retrospective Polish cohort study found that rectal lesions removed by endoscopic mucosal resection were associated with a higher likelihood of invasive cancer and recurrence than colonic lesions. The summary does not give the size of the difference.
Do these findings change treatment or follow-up recommendations?
The roundup does not report a change to clinical guidelines. It also does not provide enough detail to determine what the results mean for an individual patient; decisions about care should be discussed with a qualified health professional.
Source: medpagetoday.com
